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Over the past three decades, tremendous global progress in preventing and treating paediatric HIV infection has been achieved. This paper 
highlights the emerging health challenges of HIV-exposed uninfected (HEU) children and the ageing population of children living with 
HIV (CLHIV), summarises programmatic opportunities for care, and highlights currently conducted research and remaining research 
priorities in high HIV-prevalence settings such as South Africa. Emerging health challenges amongst HEU children and CLHIV include 
preterm delivery, suboptimal growth, neurodevelopmental delay, mental health challenges, infectious disease morbidity and mortality, 
and acute and chronic respiratory illnesses including tuberculosis, pneumonia, bronchiectasis and lymphocytic interstitial pneumonitis. 
CLHIV and HEU children require three different categories of care: (i) optimal routine child health services applicable to all children; 
(ii) routine care currently provided to all HEU children and CLHIV, such as HIV testing or viral load monitoring, respectively, and (iii) 
additional care for CLHIV and HEU children who may have growth, neurodevelopmental, behavioural, cognitive or other deficits such as 
chronic lung disease, and require varying degrees of specialised care. However, the translation thereof into practice has been hampered by 
various systemic challenges, including shortages of trained healthcare staff, suboptimal use of the patient-held child’s Road to Health book 
for screening and referral purposes, inadequate numbers and distribution of therapeutic staff, and shortages of assistive/diagnostic devices, 
where required. Additionally, in low-middle-income high HIV-prevalence settings, there is a lack of evidence-based solutions/models of 
care to optimise health amongst HEU and CLHIV. Current research priorities include understanding the mechanisms of preterm birth in 
women living with HIV to optimise preventive interventions; establishing pregnancy pharmacovigilance systems to understand the short-, 
medium- and long-term impact of in utero ART and HIV exposure; understanding the role of preconception maternal ART on HEU child 
infectious morbidity and long-term growth and neurodevelopmental trajectories in HEU children and CLHIV, understanding mental health 
outcomes and support required in HEU children and CLHIV through childhood and adolescence; monitoring HEU child morbidity and 
mortality compared with HIV-unexposed children; monitoring outcomes of CLHIV who initiated ART very early in life, sometimes with 
suboptimal ART regimens owing to medication formulation and registration issues; and testing sustainable models of care for HEU children 
and CLHIV including later reproductive care and support.
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Over the past three decades, tremendous global progress in 
preventing and treating paediatric HIV infection has 
been achieved.[1] In 2009, it was projected that 95% coverage 
of dual therapy to prevent vertical transmission of HIV with 
appropriate feeding choices could save 37  200 children’s lives 
in 2015, using 2008 data as a baseline.[2] Although life-long 
triple antiretroviral therapy (ART) for pregnant and breastfeeding 
women has not been the panacea for eliminating vertical HIV 
transmission,[1] it has certainly brought this goal significantly 
closer.[1,3] Finally, we are seeing a shift to fewer perinatally acquired 
HIV infections; however, concomitantly, owing to sustained 
high antenatal HIV prevalence, the population of HIV-exposed 
uninfected (HEU) children is steadily increasing. Additionally we 
are seeing an ageing cohort of children living with HIV (CLHIV).[4]
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Researchers associated with the South African Medical Research 
Council (SAMRC) have conducted pivotal research, firstly to prevent 
MTCT and subsequently to attain EMTCT. The current SAMRC 
president, Glenda Gray, played a key role in the first multi-country 
PErinatal TRAnsmission (PETRA)  tiral to investigate the efficacy of 
three short-course maternal and infant antiretroviral drug regimens to 
prevent MTCT.[5] The PETRA trial demonstrated that short-course, 
dual maternal antiretroviral (ARV) prophylaxis (from 36 weeks’ 
gestation until 7 days postpartum) significantly reduced MTCT 
by 4 - 8 weeks postdelivery (63% efficacy), but had no significant 
18-month benefits. This trial was followed by pivotal infant ARV 
post exposure prophylaxis research to obviate MTCT in women 
with no prior ART exposure.[6] Once South Africa (SA) adopted 
a policy to provide single-dose nevirapine to prevent vertical HIV 
transmission (PMTCT) in 18 pilot sites, the SAMRC was a key 
partner in evaluating the effectiveness of  this policy: research 
in three purposively selected sites (Paarl, Rietvlei and Umlazi) 
demonstrated 8.6%, 13.7% and 11.9% MTCT at 3 - 4 weeks,[7] and 
84%, 65% and 74% HIV-free survival at 9 months,[8] respectively, 
and poor infant feeding practices amongst HIV-negative and 
-positive mothers in the context of PMTCT.[9] After 8 years of national 
PMTCT scale-up, the SAMRC led 3 nationally representative 
evaluations in 2010, 2011 - 2012 and 2012 - 2013,[10,11] and 1 
prospective observational cohort study[12] to measure 6-week and 
18-month PMTCT effectiveness, respectively. These demonstrated 
a reduction in national 6-week MTCT to 3.5% with dual therapy 
(2008 PMTCT guidelines) and 2.6% with PMTCT Option A, and 
4.3% at 18 months, with 6.3% 18-month MTCT or death. Since 
these surveys, a SAMRC-National Institute of Communicable 
Diseases (NICD) collaboration has established that national 
laboratory data provide valid estimates of early national MTCT.[13] 
With the adoption of PMTCT Option B+ (lifelong triple ART) 
for pregnant and breastfeeding women in 2015, and the release 
of global criteria to validate EMTCT, national short- and long-
term PMTCT effectiveness needs to be monitored.[3,14,15] Despite 
a reduction in MTCT at national, provincial and district levels, 
SAMRC and partners report differential MTCT across provinces 
and districts, highlighting the gap between current case rates and 
the global target of 50 or fewer new paediatric HIV infections per 
100 000 livebirths.[16] In 2019, the SAMRC led an analysis paper on 
whether elimination of MTCT is achievable in high HIV-prevalence 
settings, highlighting how maternal HIV prevalence drives the 
paediatric HIV case rate.[17]
By 2019, SA has stabilised antenatal HIV prevalence and been hugely 
successful in reducing MTCT.[16,18,19] Expressed as a percentage of all 
births to women living with HIV (WLHIV), modelling demonstrates 
that total MTCT (perinatal and postnatal HIV transmission to end 
of breastfeeding) decreased from 31.2% (95% confidence interval 
(CI) 28.7 - 34.3) in mid-2004/05, to 5.2% (95% CI 4.5 - 6.1) in 
mid-2016/17 (Thembisa model version 4.1). Overall, perinatal HIV 
transmission decreased from 18.7% (95% CI 18.2 - 19.2) in mid-
2004/05 to 1.3% (95% CI 1.1 - 1.5) in mid-2016/17. Perinatal HIV 
transmission amongst mothers with known HIV infection was 0.84% 
(95% CI 0.78 - 0.90) in mid-2016/17. Consequently, given the stable 
antenatal HIV prevalence and reduction in MTCT, the number of 
HEU children aged 0 - 14 years increased from 1.3 million in 2004 to 
3.2 million in 2017 – this is the highest number within any country 
globally, representing 21.5% of the global HEU child population.[4] 
This paper highlights the emerging health challenges of HEU 
children and the ageing population of CLHIV, summarises 
programmatic opportunities for care, and highlights both current 
research underway and remaining research priorities in high HIV-
prevalence settings, such as SA.
What are the emerging health 
challenges faced by HEU children and 
CLHIV?
Newborn outcomes
The newborn period presents a crucial opportunity for preventing 
perinatal and postnatal HIV transmission, through identification of 
all infants born to WLHIV and stratification of mother-infant pairs 
at high or low risk of HIV transmission with appropriate postnatal 
prophylaxis, depending on risk. Furthermore, all HIV-exposed 
newborns should receive HIV testing with a polymerase chain 
reaction (PCR) test to identify in utero HIV-infected infants as early 
as possible, as immediate initiation of infant ART improves survival 
and long-term outcomes. HIV-exposed newborns, both HIV-
infected and HIV-uninfected, are more likely to start life as preterm 
infants, with lower birthweight and/or as small-for-gestational age, 
than their HIV-unexposed counterparts.[20] This effect differs by 
maternal ART regimen and timing of treatment initiation, although 
observed associations related to timing may be subject to selection 
bias.[21] Several studies have reported higher rates of preterm birth 
in infants born to women on ritonavir-boosted protease inhibitor-
containing ART than other regimens.[22-24] These adverse birth 
outcomes persist even when pregnant WLHIV receive universal 
ART with current efavirenz or dolutegravir-based regimens,[25,26] 
and are probably associated with conception on ART, particularly in 
low- and middle-income countries.[27] These adverse birth outcomes 
are poorly understood but likely to influence HEU child outcomes 
beyond birth. Additionally, the potential for teratogenic effects of 
in utero drug exposures was recently highlighted by the preliminary 
signal in Botswana of a possible association between an increased risk 
for fetal neural tube defects and dolutegravir use at time of conception.[28] 
While more definitive data are awaited, this finding highlights the 
critical need for pregnancy pharmacovigilance systems in low- and 
middle-income countries, particularly those with a high HIV burden, 
such as SA.[29]
Growth
The synergistic interactions between infection, immunity and 
childhood malnutrition are well established.[30] Indeed, malnutrition 
is sometimes referred to as an immunodeficiency syndrome as it is a 
composite outcome of several inflammatory and metabolic pathways.[31] 
Infectious diseases such as HIV infection exacerbate undernutrition. 
In a prospective cohort study conducted prior to the availability of 
maternal ART, Ramokolo and colleagues reported worse postnatal 
growth velocity in SA CLHIV than HIV-unexposed and HEU 
children.[32] Consistent with other studies,[33] no significant differences 
in growth were observed between HIV-unexposed and HEU children. 
However, recent data show poorer early growth of HEU children, and 
notably suboptimal growth and failure to catch up postnatally in HEU 
infants born small for gestational age compared with HIV-unexposed 
infants.[34] This observation suggests a fetal origin to later poor HEU 
child outcomes that requires further interrogation.[35] Data also show 
that maternal HIV infection is associated with several adverse birth 
outcomes such as low birthweight, preterm birth, small-for-gestational 
age and stillbirth.[36-38] Additionally, HEU children in the era of 
Option B+ have poorer height growth compared with weight, and 
therefore higher BMI, and obesity remain a concern in adolescence 
and adulthood (du Plessis – in press). The mechanisms behind 
these observations remain unclear. Some speculate that immune 
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dysfunction induced by HIV exposure may partly explain the growth 
faltering.[39] There is also evidence that in utero exposure to maternal 
ART increases the risk of suboptimal birth outcomes, leading to 
poorer growth postnatally.[35,40] As countries adopt lifelong ART for 
pregnant and lactating women (WHO Option B+ policy), more 
women with higher CD4 counts will conceive on ART. Few data 
are available on these women and their children. Further research 
is therefore required to understand the interplay between HIV and 
growth in the current ART era to ensure that HIV-exposed children 
not only survive but also thrive.
Early neurodevelopment
Neurological, developmental and behavioural problems in CLHIV 
have been well-established as devastating consequences of HIV 
infection, ranging from cognitive deficits to HIV encephalopathy,[41-43] 
and these are associated with neuro-radiological findings.[44,45] Since the 
introduction of paediatric ART, studies have continued to document 
neurodevelopmental impairment.[46-48] Furthermore, there is growing 
evidence that HEU children may experience early developmental 
impairment. Previous reviews have reported some delays in cognitive, 
language or motor development,[47,49,50] although to a lesser extent 
than in CLHIV and mainly in low-resource settings.[47] A recent study 
from SA found motor and cognitive delay, particularly associated with 
preterm birth,[51] and a study from Zambia reported a later impact 
on school performance.[52] However, other studies in Botswana[53] 
and SA[54] have not found substantial differences when compared 
with HIV-unexposed children, although some language impairment 
was demonstrated, which has also been seen in high-income 
settings.[55] Further research and follow-up of both CLHIV and HEU 
children in the current ART era is needed to determine the nature 
of the developmental delay as well as the long-term implications. 
In addition, investigating the mechanisms behind the impaired 
development is important to prevent future developmental delay, and 
to understand the complex combination of HIV-related variables and 
illness, ART exposure and side-effects, and socioeconomic factors.
Later mental health and neurocognitive development
The impact of perinatal HIV transmission is experienced well 
into adolescence, where HIV has historically been implicated in 
normative developmental challenges, including pubertal delays,[56] 
continued neurodevelopmental and cognitive problems[57,58] as well 
as greater social and emotional immaturity relative to same-age 
peers.[59] The most common mental health problems seem to be 
attention deficit hyperactivity disorder, mood disorder, anxiety 
disorder and substance use disorder.[60] However, not all adolescents 
living with HIV (ALHIV) experience the same level of vulnerability, 
as these disorders range from 8% to 60% in untreated HIV-infected 
adolescents.[60] The evidence from high-income settings suggests 
that CLHIV are at significant risk for mental health problems and 
substance use when entering adolescence.[61] Additionally, there 
is limited but growing research which suggests that youth living 
with perinatally acquired HIV infection may be equally, if not 
more, vulnerable to emotional and behavioural problems than HEU 
youth or HIV-uninfected youth living in households affected by 
HIV.[62,63] Recent SA data warned against conflating all HIV-infected 
adolescents: perinatally infected adolescents were more likely to be 
ART adherent, retained in healthcare and treated well by clinic staff 
than horizontally infected adolescents who display more mental 
health disorders than the former.[64] These better outcomes amongst 
perinatally infected adolescents are substantiated by a recent SA 
study which described a lower incidence of behavioural problems 
amongst perinatally acquired ALHIV, compared with uninfected 
adolescents.[65] In addition, the loss of adult caregivers to HIV, 
and poverty related to loss of income due to ill health, may also 
compromise the family’s capacity to meet the needs of ALHIV.[66]
Infectious disease morbidity and mortality
Without ART, over 50% of CLHIV would die before age 2 
years.[67] Recent studies indicate that, despite early introduction of 
ART, child mortality in CLHIV remains high and viral suppression is 
often suboptimal, with substantial implications for future health 
outcomes.[68,69] HEU children have also been found to have a higher 
mortality than HIV-unexposed children,[67,70] particularly in the first 
years of life, estimated to be ~double that of HIV-unexposed children, 
although reports vary across countries.[71,72] Data from SA suggest that 
the excess mortality in HEU children contributes substantially to total 
infant mortality.[73] HEU child mortality appears to be predominantly 
due to infectious causes,[74] and SA studies have shown that HEU 
infants have a higher incidence as well as greater risk for mortality 
from invasive pneumococcal disease and viral respiratory infections.[75,76] 
Prolonged breastfeeding, although with overwhelming benefits for 
improved nutrition and reduced diarrhoeal disease morbidity, did 
not prevent additional respiratory morbidity and mortality in HEU 
children from two different urban settings (Soweto and Paarl).[77,78] 
Furthermore, in studies from Botswana, cotrimoxazole prophylaxis 
did not reduce infectious morbidity or improve survival in HEU 
children in the first year of life.[79] Promising evidence from high-
income settings suggests initiation of maternal ART before pregnancy 
may mitigate some of this infectious morbidity risk for HEU children; 
however, this still requires evaluation in HIV high-burden countries.[80]
Respiratory-related morbidity and mortality
Respiratory disease including tuberculosis and viral and bacterial 
infections remains the primary cause of hospital admissions in 
CLHIV despite early ART.[68] This finding is similar for HEU 
children, who also have increased rates of hospitalisation and 
suffer from more severe and unusual infectious diseases in the 
early years of life,[81,82] particularly pneumonia.[83] Although there is 
considerable difficulty estimating the association between HIV and 
pulmonary tuberculosis (PTB) in African children, the epidemiology 
of childhood TB and HIV overlap considerably.[84,85] Routine 
programmatic data from Cape Town prior to the paediatric ART 
roll-out reported a TB incidence of 1 596 per 100 000[86] in CLHIV, 
decreasing considerably following ART access,[87,88] and linked also to 
a reduction in associated hospitalisations.[89] HIV infection associated 
with multidrug-resistant (MDR) paediatric TB is a challenge, and SA 
studies reported a paediatric HIV prevalence of 54%, 77% and 43% 
amongst children with MDR TB in Johannesburg, KwaZulu-Natal 
and Cape Town, Western Cape in 2008, 2009 - 2010 and 2003 - 2008 
respectively.[90-92] Amongst HEU children, data demonstrate that the 
incidence of TB is four times higher than in the general population.[84] 
Pneumocystis pneumonia (PJP) remains an important cause of severe 
pneumonia in HEU children and CLHIV: a prospective intervention 
study conducted in Steve Biko Academic Hospital, Pretoria, SA, 
demonstrated co-infection between PJP and cytomegalovirus (CMV), 
with a 30% mortality rate.[93] There is compelling evidence that infant 
ART decreases mortality from invasive pneumonia by 62.5% in SA 
and protects against hospitalisation and mortality from influenza.[84] 
Data are needed on the impact of PMTCT Option B+ and of early 
infant HIV diagnosis with early infant ART initiation on childhood 
respiratory diseases amongst CLHIV. Chronic lung disease (CLD), 
including bronchiectasis and lymphocytic interstitial pneumonitis, is 
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an unresolved challenge in CLHIV, despite 
ART. A Zimbabwean study by Ferrand et al.[94] 
demonstrated that ~45% of CLHIV aged 
0 - 14 years receiving HIV-related care, 
have CLD, even at high CD4 cell counts 
and despite ART access. Data on acute and 
chronic lung disease in CLHIV in SA are 
sparse. Weber et al.[95] reporting on data 
from 56 children aged 5 years (interquartile 
range 2 - 8 years) demonstrated a 
significant association between CLD and 
lung hyperinflation and hyperpigmented skin 
lesions. Calligaro and Gray,[96] using data 
from Cape Town, SA, demonstrated increased 
airway resistance in HIV-infected v. HIV-
uninfected children, and that an abnormal 
forced expiratory volume in one second 
(FEV1) was significantly correlated with high 
airway resistance. Like Ferrand et al.,[94] they 
concluded that lung involvement occurs early 
in CLHIV who do not access ART and 
that clinical and immunological correlates 
are poor predictors of lung involvement. 
More data are needed to understand these 
mechanisms. Additionally, data on the 
lung microbiome in CLHIV are limited, 
warranting further investigation.
What health services/
programmes exist to 
meet the needs of HEU 
children and CLHIV?
CLHIV and HEU children require 
three different categories of care.[97] The 
first entails optimal routine child health 
services applicable to all children, including 
immunisations, growth monitoring and 
nutritional support, as well as diagnosis and 
management of acute childhood illnesses. 
The second category pertains to the routine 
care currently provided to all HEU children 
and CLHIV, such as HIV testing at specified 
intervals (for HEU children), antiretroviral 
prophylaxis (for HEU children) or viral 
load monitoring (for CLHIV). Both these 
aspects of care are relatively well catered 
for and resourced through the Integrated 
Management of Childhood Illnesses (IMCI) 
strategy and supported by the Road to 
Health booklet (RTHB).The concept of 
what constitutes ‘routine care’ and ‘success’ 
in terms of the PMTCT programme, 
however, requires a paradigm shift in SA. 
The current major endpoint of the PMTCT 
programme is a child who is HIV free. A 
more progressive view of success would be 
a child who is HIV free, thriving, and has 
normal neurodevelopment, for which the 
third category of care is also required. The 
third category is additional care for CLHIV 
and HEU children who may have growth, 
neurodevelopmental, behavioural cognitive 
or other deficits such as chronic lung disease, 
and require varying degrees of specialised 
care. The new national PMTCT guideline 
(2019) identifies the HEU child as being at 
risk for poorer outcomes and recommends 
vigilance to identify vulnerabilities. The 
RTHB, the IMCI strategy, and the School 
Health Programme have included screening 
for developmental impairments in routine 
care for all children, including HEU children 
and CLHIV.[98] However, the translation 
thereof into practice has been hampered 
by various systemic challenges, including 
shortages of trained healthcare staff, 
suboptimal use of the patient-held RTHB for 
screening and referral purposes, inadequate 
numbers and distribution of therapeutic 
staff, lack of long-term follow-up of HEU 
children and adolescents, and shortages of 
assistive/diagnostic devices where required.[18]
What policy- and health 
system-related research 
has just been completed 
in SA or is underway?
The very early infant diagnosis 
study conducted at Kalafong hospital 
substantiates the current policy of universal 
rather than targeted birth HIV testing 
amongst HIV-exposed newborns. The study 
demonstrated that using a risk score (three- 
or four-risks) at a probability of 0.02 and 
0.04, misses 20% and 24% of HIV-infected 
infants, respectively, at birth compared with 
universal testing.[99] A field-based evaluation 
of point-of-care testing for at-birth infant 
HIV diagnosis, conducted at Rahima Moosa 
Hospital, highlighted the additional staff 
needed to make this approach functional; 
however, the study highlighted the potential 
child health gains as time to infant ART 
initiation was reduced.[100] The PHANGISA 
study will assess the role of viral load and 
health systems factors in driving peripartum 
and postpartum MTCT, in the context of 
PMTCT Option B+, in Ehlanzeni, a rural 
district in SA (http://www.mrc.ac.za/
intramural-research-units/HealthSystems-
current-projects).
Research priorities in 
high HIV-prevalence 
settings
CLHIV and HEU children experience 
unique health challenges that require 
vigilance and ongoing, long-term 
surveillance. This need is especially 
important, given the increasing HEU 
child population in SA and globally. Care 
needs to be provided in a non-stigmatising 
way, and front-line health workers should 
be aware of the vulnerabilities of these 
populations.
Several research gaps exist for CLHIV 
and HEU children in high HIV-prevalence 
settings (Fig. 1), including understanding 
mechanisms of preterm birth in WLHIV, 
to optimise preventive interventions; 
Fig. 1. Research priorities in high HIV-prevalence settings. (WLHIV = women living with HIV;  
ART = antiretroviral therapy; HEU = HIV-exposed uninfected; CLHIV = children living with HIV.)
Pregnancy and 
peripartum
• Mechanisms of
preterm birth in 
WLHIV to identify 
preventive 
interventions.
• Pregnancy 
pharmacovigilance 
systems to 
understand the 
short-, medium- and 
long-term impact of 
in utero ART, and HIV 
exposure.
Infancy and childhood
• Role of preconception ART on
infant and later infectious 
disease morbidity and 
mortality and child health 
outcomes.
• Long-term growth and
neurodevelopmental 
trajectories in HEU children and
CLHIV, and how to optimise 
these.
• Mental health amongst HEU
children and CLHIV.
• Education outcomes amongst
HEU children and CLHIV.
• HEU child morbidity and
mortality compared with 
HIV-unexposed  children.
• Outcomes of CLHIV who
initiated ART early.
• Chronic diseases in CLHIV
including lung health in CLHIV.
Adolescence
• Mental health, substance use
and long-term outcomes 
amongst HEU adolescents and 
perinatally infected CLHIV.
• Dierences in health and
behavioural outcomes 
amongst perinatally v. 
horizontally infected 
adolescents.
• Chronic diseases in perinatally
infected CLHIV including lung 
health in CLHIV.
Detailed mechanistic studies of in utero HIV and ART-exposure on later life health trajectories.
Health systems research – on how to provide optimal care (best models of care) for HEU and CLHIV 
in low- and middle-income settings.
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establishing pregnancy pharmacovigilance systems to understand 
the short-, medium- and long-term impact of in utero ART and HIV 
exposure; understanding the role of preconception maternal ART on 
infant infectious morbidity, understanding the role of preconception 
maternal ART on HEU children’s infectious morbidity and long-term 
growth and neurodevelopmental trajectories in HEU children and 
CLHIV; understanding mental health outcomes and support required 
in HEU children and CLHIV through childhood and adolescence; 
monitoring HEU child morbidity and mortality compared with HIV-
unexposed children; monitoring outcomes of CLHIV who initiated 
ART very early in life, sometimes with suboptimal ART regimens 
due to medication formulation and registration issues; and testing 
sustainable models of care for HEU children and CLHIV including 
later reproductive care and support. Lastly, we must not lose sight 
of the urgent need to reduce maternal HIV prevalence, as this is the 
most important way to reduce the numbers of CLHIV and HEU.
Conclusion
More than one in five children in SA are HIV- and ART-exposed 
in utero; never before has there been exposure to an infectious disease 
or associated medication use of this magnitude during pregnancy. SA 
needs to lead the way in better understanding the vulnerabilities of 
HEU children and CLHIV, to optimise their short- and long-term 
outcomes.
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